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Backgroud: Peri-implant mucositis and peri-implantitis are the main biological complications associated with 
dental implants. Since most authors agree that bacteria play a major etiological role, the main aims of this study 
were to determine if a formulation of erythritol and chlorhexidine applied with an air polishing system inhibits 
biofilm re-growth over dental implants and to compare the decontamination capacity of this therapy with that of 
mechanical removal by saline and gauze.
Material and Methods: A multispecies biofilm (P. gingivalis, A. actinomycetemcomitans, F. nucleatum, A. naes-
lundii, V. parvula and S. oralis) was grown for 14 days on 52 dental implants in an artificial mouth. These implants 
were divided into three groups according to the applied treatment: 14 negative control (CON), 19 erythritol-
chlorhexidine (ERY) and 19 gauze with saline (GAU) samples. Twelve dental implants from the ERY and GAU 
groups and 8 implants from the CON group were re-incubated for 7 additional days after treatment. The bacterial 
count was performed by quantitative polymerase chain reaction (qPCR) using propidium monoazide (PMA). A 
descriptive and bivariate analysis of the data was performed.
Results: The erythritol and chlorhexidine formulation significantly inhibited biofilm regrowth in comparison with 
the mechanical treatment (GAU), since a significant decrease in all the species was observed in the ERY group 
(except for Aggregatibacter actinomycetemcomitans). The antibiofilm and antibacterial capacity of the two active 
treatment groups (ERY and GAU) was similar for a 14 days multispecies in vitro biofilm, except for the lower 
count of A. naeslundii in the GAU group.
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Introduction
Dental implants have become the gold standard when 
aiming at reconstruction of missing teeth. Several 
studies have proven dental implants to be a reliable 
alternative for providing function and aesthetics with 
long-term success. However, with increasing numbers 
of fixtures being installed yearly, there has also been a 
significant increase in peri-implant diseases (1).
Mucositis and peri-implantitis are the main biological 
complications associated with dental implants (2,3). 
Data indicate that bacteria play a major etiological 
role in the development of these complications, sev-
eral treatment strategies have been developed with the 
aim of reducing the bacterial count, decontaminating 
the implant surface and removing the biofilm (4). Bio-
films are surface-adhered microbial communities em-
bedded in a self-produced matrix (5). These organized 
communities represent a significant health risk due to 
their resistance to host-defense mechanisms and their 
decreased susceptibility to conventional antimicrobials. 
Biofilm-mediated resistance has been attributed to im-
paired penetration of antimicrobials through the matrix, 
increased expression of drug-resistance genes, and re-
duced metabolic activity of cells residing in the biofilm. 
Because of their involvement in bacterial infections in 
humans, biofilms have been the subject of intensive re-
search for many years (5).
 Polymerase chain reaction (PCR) techniques have 
shown several advantages over traditional microbiolog-
ic culture methods. They are faster and have a higher 
specificity and sensitivity for identifying and quantify-
ing oral bacteria. Nevertheless, PCR might overesti-
mate the number of active bacteria because it does not 
differentiate DNA coming from live or dead microor-
ganisms. Thus, the use of propidium monoazide (PMA) 
is of great interest since it allows to detect cell mem-
brane integrity, distinguishing viable and irreversibly 
damaged cells (6-10).
Regarding the treatment of peri-implant diseases, a va-
riety of different approaches have been proposed, rang-
ing from non-surgical therapy to laser disinfection or to 
surgical treatments with either resective or regenerative 
approaches (11). The ideal treatment should focus not 
only on removing pathogens from the implant surfaces, 
but also on preventing bacterial regrowth over the area. 
This is a crucial issue, since one of the main treatment 
goals should be to prevent the adhesion of primary colo-
nizers to the recently decontaminated implant surfaces. 
However, knowledge on this process is still very scarce.
A minimally abrasive powder containing erythritol 
and 3% chlorhexidine has been considered a promising 
treatment option for the removal of subgingival biofilm 
(12,13). A recent systematic review and meta-analysis 
showed that erythritol/chlorhexidine was superior or 
equal to other methods when applied over contaminat-
ed implant surfaces, and was more biocompatible (14). 
However, few studies have been performed to evaluate 
the anti-biofilm regrowth properties of this formulation.
For this reason, the present in vitro study was conducted 
with the following aims: to determine if a formulation 
of erythritol and 3% chlorhexidine applied with an air 
polishing system inhibits biofilm regrowth over dental 
implants and to compare the decontamination capacity 
of this therapy with those of mechanical removal with 
saline and gauze.
Material and Methods 
A randomized, single-blind, in vitro study was carried 
out. Fifty-two dental implants (Avinent, Santpedor, Bar-
celona, Spain) were subjected to in vitro multi-species 
biofilm formation in the microbiology department of 
the Dentaid Research Center (Dentaid SL, Cerdanyola 
del Vallès, Spain). Decontamination of the implants 
was randomly performed either with erythritol powder 
with 3% of chlorhexidine (Air Flow Powder Plus, EMS, 
Nyon, Switzerland) using an air-flow device (EMS, 
Nyon, Switzerland) or with a gauze swab with sterile 
saline solution. A single clinician performed these pro-
cedures for the time considered necessary to remove the 
biofilm adequately according to the clinician’s profes-
sional criterion. The implants were then coded to avoid 
bias in the microbiology analysis.
- Biofilm development on implant surfaces
Oral biofilms were grown in an artificial mouth model 
in an anaerobic atmosphere (15) using the following 
bacterial species: Streptococcus oralis DSM 20627, 
Veillonella parvula NCTC 11810, Actinomyces naes-
lundii DSM 17233, Fusobacterium nucleatum DSM 
20482, Porphyromonas gingivalis ATCC 33277 and 
Aggregatibacter actinomycetemcomitans DSMZ 8324. 
The bacteria were kept on blood agar plates (Oxoid No. 
2; Oxoid Ltd, Basingstoke, UK) with 5% horse blood, 
5mg/L hemin and 1 mg/L menadione at 37ºC under an-
aerobic conditions, while BHI-II medium was employed 
for both the liquid cultures and biofilm growth. All the 
species were inoculated simultaneously from exponen-
Conclusions: The use of erythritol powder with chlorhexidine applied with an air polishing system reduces biofilm 
regrowth over dental implants when compared with mechanical removal by saline and gauze. This effect might be 
beneficial for patients included in peri-implant maintenance programs.
Key words: Dental implants, biofilms, peri-implantitis, erythritol, chlorhexidine.
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The regrowth process took place under the same condi-
tions as the initial biofilm development. After this incu-
bation time, all the regrowth implants were processed 
for genomic DNA extraction.
-Propidium monoazide (PMA) treatment, DNA extrac-
tion and quantitatve PCR (qPCR)
qPCR was used to determine the total number of cells 
of each species that formed the biofilms on the implants, 
while the live cell count was determined by PMA-qPCR 
(16). For this purpose, the implants were washed by im-
mersing them three times in PBS. The biofilms were dis-
persed using a vortex for 5 minutes in 1 mL of PBS. The 
PMA treatment prior to genomic DNA extraction was 
performed as described by Àlvarez et al. (16). Genomic 
DNA extraction was effected using the QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany), following a pre-
viously published protocol (15). Quantitative PCR was 
performed with a LightCycler 480 II Instrument and the 
LightCycler 480 II Probes Master kit (Roche Diagnostics, 
Penzberg, Germany) and specific primers (Invitrogen 
Life Technologies, Carlsbad, CA, USA) and probes (Ap-
plied Biosystems, UK and Roche Diagnostics, Penzberg, 
Germany) were used. Data analysis was performed with 
LightCycler 480 Software 1.5 (Roche Diagnostics) using 
the second derivative maxim method. The qPCR reaction 
was conducted using an initial cycle of 95°C for 10 min-
utes, followed by 40 cycles of denaturation at 95°C for 10 
tial phase cultures, except for P. gingivalis, which was 
inoculated 24 hours previously in the bioreactor. The 
bacteria were kept in a continuous culture for 5 days. 
Subsequently, they were transferred to the device where 
the implants were located, bathing them totally for 14 
days at a flow rate of 30 mL/h, in anaerobic conditions, 
at 37ºC and pH 7.2 (15).
- Experimental treatments
After 14 days in the artificial mouth, the implants were 
removed from the device and assigned randomly, using 
a computer-generated sequence (www.randomization.
com, accessed on February 18, 2019), to one of the study 
groups: erythritol powder with 3% of chlorhexidine 
(ERY group); gauze with sterile saline (GAU group) or 
negative control (CON group) (Fig. 1). Fourteen nega-
tive control implants were immersed three times in 
phosphate buffered saline (PBS) (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). 
Of these, 6 were then processed for genomic DNA ex-
traction and 8 were placed in a new sterile vessel for 
regrowth. In the ERY group, 19 implants were treated 
with chlorhexidine-enriched erythritol powder, applied 
with an air-polishing device. Seven were processed for 
genomic DNA extraction and 12 were re-incubated for 7 
days after treatment. In the GAU group, the same num-
ber of implants were treated mechanically (gauze with 
sterile saline) and analyzed (Fig. 1) or used for regrowth.
Fig. 1:Flow diagram of the present study.
qPCR: Quantitative polymerase chain reaction; PMA: Propidium monoazide.
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seconds, annealing at 60 °C for 30 seconds, and extension 
at 72°C for 1 second. Standard curves for each bacterial 
species were developed as described in Àlvarez et al. (16).
- Microscopic analysis
Two implants from each group were randomly select-
ed for analysis by confocal laser scanning microscopy 
(Leica TCS SP5, Leica Microsystems, Heidelberg, 
Germany). After a washing procedure to remove non-
adhered bacteria, the implant biomass was dyed with 
SYTO9 nucleic acid stain (Molecular Probes, Eugene, 
OR, USA) at room temperature in the dark for 10 min-
utes. Six fields per implant were acquired with a 10x ob-
jective, with the white laser set at 482 nm. Imaris® v.7.1 
software (Bitplane AG, Badenerstrasse, Zurich, Swit-
zerland) was used to obtain a 3D reconstruction of each 
field from the optical sections. Due to the results found in 
the ERY group (recolonization), 2 negative control im-
plants and 2 implants treated with erythritol were exam-
ined under a scanning electron microscope (Merlin FE-
SEM®, Carl Zeiss, Oberkochen, Germany) at 30,000x 
in order to detect surface alterations after treatment.
- Statistical analysis
A descriptive analysis of the data was performed with 
the Statistical Package for Social Sciences software 
(SPSS v22.0; IBM Corp, Armonk, New York). Kruskal 
Wallis tests and Mann-Whitney U-tests were employed 
to detect differences between the 3 groups. The level of 
significance was set at p < 0.05.
Results
The results concerning the effect of the 3 treatments 
on a 14-day multispecies biofilm can be observed in 
Table 1. The groups showed similar qPCR results for 
most of the bacteria. However, the mechanical treat-
ment (GAU group) had a lower total count (qPCR) of 
A. naeslundii and P. gingivalis than the CON group 
(p= 0.01 and p= 0.026, respectively). No significant 
differences were found when comparing the two active 
treatment groups (ERY and GAU), except in A. naes-
lundii, which had a lower bacterial count in the GAU 
group (p= 0.022; Table 1). Regarding the PMA-qPCR 
results, the number of live P. gingivalis cells was sig-
nificantly lower in the ERY group than in the CON 
group, while the number of live A. actinomycetemcom-
itans cells was lower in both treatment groups (ERY 
and GAU) than in the CON group.
The outcomes of the second phase of the study (biofilm 
regrowth after treatment), which are related with the main 
study aim, are presented in Table 2. In comparison with 
the standard mechanical therapy (GAU), the ERY group 
was found to present a significant reduction in biofilm 
regrowth after therapy for all species except A. actino-
mycetemcomitans (qPCR and PMA-qPCR) and S. oralis 
(PMA-qPCR). To evaluate the resilience of the biofilms af-
ter application of the therapies, the PMA-qPCR ratios (fol-
lowing treatment after 14 days of biofilm growth and after 
7 days of biofilm regrowth) were compared (Fig. 2, Fig. 3).
Bacterial species qPCR PMA-qPCR
ERY GAU CON Bivariate ERY GAU CON Bivariate













ERY vs. GAU 0.234
ERY vs. CON 0.945 ERY vs. CON 0.639













ERY vs. GAU 0.343
ERY vs. CON 0.445 ERY vs. CON 0.639













ERY vs. GAU 0.445
ERY vs. CON 0.315 ERY vs. CON 0.755













ERY vs. GAU 0.128
ERY vs. CON 1.000 ERY vs. CON 1.000













ERY vs. GAU 0.445
ERY vs. CON 0.073 ERY vs. CON 0.003















ERY vs. GAU 0.383
ERY vs. CON 0.534 ERY vs. CON 0.003
GAU vs CON 0.181 GAU vs CON 0.343
qPCR: quantitative polymerase chain reaction; PMA: propidium monoazide; ERY: erythritol powder with 3% of chlorhexidine group; GAU: gauze 
with sterile saline group; CON: negative control group; SD: Standard deviation.
Table 1: Main results for the 3 treatment groups (ERY, GAU and CON) in the first phase of the study (after treatment following 14 days of bio-
film growth) stratified by logarithms of bacterial species.
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Bacterial species
qPCR PMA-qPCR
ERY GAU CON Bivariate ERY GAU CON Bivariate
(7-day biofilm 
regrowth)













ERY vs. GAU 0.203
ERY vs. CON 0.000 ERY vs. CON 0.109













ERY vs. GAU 0.001
ERY vs. CON 0.000 ERY vs. CON 0.000













ERY vs. GAU 0.036
ERY vs. CON 0.031 ERY vs. CON 0.022













ERY vs. GAU 0.020
ERY vs. CON 0.000 ERY vs. CON 0.000













ERY vs. GAU 0.009
ERY vs. CON 0.041 ERY vs. CON 0.203















ERY vs. GAU 0.880
ERY vs. CON 0.026 ERY vs. CON 0.020
GAU vs. CON 0.031 GAU vs. CON 0.025
qPCR: quantitative polymerase chain reaction; PMA: propidium monoazide; ERY: erythritol powder with 3% of chlorhexidine group; GAU: 
gauze with sterile saline group; CON: negative control group; SD: Standard deviation.
Table 2: Main results for the 3 treatment groups (ERY, GAU and CON) in the second phase of the study (after 7 days of biofilm regrowth fol-
lowing treatment), stratified by logarithms of bacterial species.
CON: Control group; GAU: Gauze group; ERY: Erythritol and chlorhexidine group; logPMAVp: Logarithm of 
Veionella parvula count with PMA-qPCR; logPMAAn:; Logarithm of Actinomyces naeslundii count with PMA-
qPCR; logPMAAa: Logarithm of Aggregatibacter actinomycetemcomitans count with PMA-qPCR; logPMASo: 
Logarithm of Streptococcus oralis count with PMA-qPCR; logPMAFn: Logarithm of Fusobacterium nucleatum 
count with PMA-qPCR; logPMAPg: Logarithm of Porphyromonas gingivalis count with PMA-qPCR; Outlier 
(º); extreme (*).
Fig. 2: Comparison between the PMA-qPCR ratios of the 3 groups following treatment of a 14-day biofilm.
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GAU: Gauze group; ERY: Erythritol and chlorhexidine group; logPMAVp: Logarithm of Veionella parvula count 
with PMA-qPCR; logPMAAn:; Logarithm of Actinomyces naeslundii count with PMA-qPCR; logPMAAa: Log-
arithm of Aggregatibacter actinomycetemcomitans count with PMA-qPCR; logPMASo: Logarithm of Strepto-
coccus oralis count with PMA-qPCR; logPMAFn: Logarithm of Fusobacterium nucleatum count with PMA-
qPCR; logPMAPg: Logarithm of Porphyromonas gingivalis count with PMA-qPCR; Outlier value (º); Extreme 
value (*).
Fig. 3: Comparison between the PMA-qPCR ratios of the 2 active groups after therapy and 7-day biofilm regrowth.
The ERY biofilms showed the lowest ratios for most of 
the species, indicating low regeneration of the biofilm 
after this treatment. The confocal optical microscope 
images also support these results, since the biofilm 
coverage area was smaller on the ERY group implants 
(Fig. 4).
Scanning electronic microscopy (SEM) disclosed that 
the 2 implants of the ERY group displayed attached par-
ticles of approximately 0.1 μm in size firmly attached to 
the implant surface. These particles were not found in 
the negative control implants.
Fig. 4: Confocal microscopy images after 7 days of biofilm recolonization of the surface of a dental implant. A: Control group, B: Gauze group, 
C: Erythritol and chlorhexidine group.
Discussion
The present study shows that applying an erythritol-
enriched powder with 3% of chlorhexidine through 
an air-flow device inhibits biofilm regrowth on dental 
implants in comparison with debridement with a gauze 
with sterile saline solution. However, these therapies 
have proved to give similar results for removing already 
established biofilms.
This research has some limitations that must be men-
tioned. Firstly, the in vitro biofilm employed is not ex-
actly the same as the one that a clinician might find in 
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a patient. However, this oral biofilm included several 
bacterial species (multispecies) and was produced us-
ing a dynamic model (artificial mouth) that simulated 
real crevicular flow conditions. Thus, this method over-
comes most of the limitations of the static in vitro bio-
film traditionally employed (15,17). Moreover, using 
PMA-qPCR provides important information, since it 
determines the bacterial count of live microorganisms 
present in the biofilm. Secondly, the therapies were ap-
plied under ideal conditions of accessibility and light. 
Certainly, this allowed the researcher to perform a more 
thorough decontamination of the implants in compari-
son with the standard clinical environment. For exam-
ple, the lower areas of the implants’ threads are usu-
ally more difficult to access with air-polishing systems, 
since a bone defect might prevent direct application of 
the powder in these zones (18). Nevertheless, this situ-
ation probably affected both active treatment groups 
equally and therefore did not favor one group over the 
other. Finally, some available antibiofilm treatments 
could not be included in the present study. Thus, future 
research should compare the disinfection properties of 
the erythritol-chlorhexidine formulation with those of 
other active therapies (Er:YAG laser, chlorhexidine so-
lutions, glycine powder, among others).
Peri-implant diseases are the most prevalent biological 
complication associated with dental implants. The esti-
mated prevalence of peri-implantitis ranges from 14% 
to 30%, while mucositis affects 32% to 54% of patients 
(19). A recently-published private-practice sample with 
full-arch rehabilitations has shown that these figures 
might be even higher, as more than half of the patients 
were diagnosed with a peri-implant disease (20). Ac-
cording to the 2017 World Workshop on the Classifi-
cation of Periodontal and Peri-Implant Diseases and 
Conditions (21), peri-implantitis is a plaque-associated 
pathological condition occurring in tissues around den-
tal implants, characterized by inflammation in the peri-
implant mucosa and subsequent progressive loss of sup-
porting bone. Initial bacterial colonization at implant 
surfaces occurs within 30 minutes, while a mature sub-
gingival microbiota can be observed within a week (22). 
According to Cortés-Acha et al. (23), a wide variety of 
bacteria can be identified in healthy dental implants af-
ter 14 days of exposure to the oral environment. Also, 
a global plaque coverage of the implants is expected, 
even in the subgingival area (24). All this information 
highlights that plaque control and biofilm removal are 
paramount for preventing and treating these biological 
complications. Chemical and physical (mechanical or 
laser) decontamination strategies have been described 
in the literature (4). A meta-analysis to determine the 
most effective non-surgical therapy for the management 
of peri-implantitis concluded that local application of 
antibiotics, the use of glycine-powder applied with an 
air-polishing system, and Er:YAG laser seemed to sig-
nificantly reduce soft tissue inflammation (bleeding on 
probing: BoP) (25). However, to the best of the present 
authors’ knowledge there is no clear evidence that any 
mechanical or chemical biofilm decontamination tech-
nique is superior to others. This also seemed to be the 
case in the present sample, where the standard mechani-
cal therapy (gauze with sterile saline) had a similar an-
tibacterial effect to that of the erythritol-chlorhexidine 
treatment. However, this paper adds new and clinically 
relevant information regarding bacterial recolonization 
of a recently decontaminated dental implant surface. 
The selection of the most suitable decontamination 
therapy should take into consideration not only the im-
mediate anti-biofilm effect but also its duration. Indeed, 
inhibition of bacterial regrowth after therapy might play 
a critical role in the prevention and progression of both 
mucositis and peri-implantitis. According to the results 
of the present study, erythritol-enriched powder with 
3% of chlorhexidine seems to be a valid option for use 
in peri-implant maintenance programs, since it might 
inhibit colonization of the dental implants during the 
first days after treatment.
Air-polishing systems have been used in dentistry for 
several indications, some of which seek the removal of 
oral biofilms (26,27). Some in vitro studies have shown 
that air-polishing sprays seem to achieve better biofilm 
removal outcomes than other mechanical systems (e.g., 
plastic curettes and vector system) or lasers (Er:YAG 
and Er,Cr:YSGG) on micro-structured titanium sur-
faces (26). However, abrasive substances like sodium 
bicarbonate might cause undesirable alterations to im-
plant surfaces (28-30). Glycine powder grants the same 
antibiofilm efficacy with minimal damage to the tita-
nium, due to its low abrasiveness (29). Other agents that 
have also been tested include erythritol, which produces 
DNA and RNA depletion, attenuates extracellular ma-
trix production, and alters dipeptide acquisition and 
amino acid metabolism, leading to inhibition of biofilm 
development (31). Erythritol has shown promising re-
sults under in vitro conditions, but also in real clinical 
scenarios. A recent randomized clinical trial has dem-
onstrated the effectiveness of this powder in removing 
dental plaque during repeated instrumentation of re-
sidual pockets in supportive periodontal therapy (12). 
To summarize, erythritol seems to induce a change in 
the oral microbiota, shifting it towards a more favor-
able environment where the traditional colonizers are 
predominant (32). One possible explanation for these 
positive outcomes might be related to the attachment 
of erythritol/chlorhexidine particles to the dental im-
plants. Indeed, implants from the ERY had 0.1 μm par-
ticles attached to the implant surface. More studies are 
required to confirm that these particles have a clinically 
relevant effect.
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In conclusion, the use of erythritol powder with 3% 
chlorhexidine applied with an air polishing system 
seems to inhibit biofilm regrowth over recently decon-
taminated dental implants. However, this combination 
of erythritol/chlorhexidine seems to have a similar de-
contamination capacity of a simple mechanical removal 
(gauze with saline) in already established oral biofilms. 
Further studies are required to compare this formula-
tion with other decontaminants and to validate the re-
sults of this in vitro study.
References
1. Suárez-López del Amo F, Yu SH, Wang HL. Non-surgical therapy 
for peri-implant diseases: a systematic review. J Oral Maxillofac 
Res. 2016;7:e13.
2. Zitzmann NU, Berglundh T. Definition and prevalence of peri-
implant diseases. J Clin Periodontol. 2008;35:286-91.
3. Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. J Clin 
Periodontol. 2018; 45:S246-66.
4. Mellado-Valero A, Buitrago-Vera P, Solá-Ruiz MF, Ferrer-García 
JC. Decontamination of dental implant surface in peri-implanti-
tis treatment: A literature review. Med Oral Patol Oral Cir Bucal. 
2013;18:e869-76.
5. Singh S, Singh SK, Chowdhury I, Singh R. Understanding the 
mechanism of bacterial biofilms resistance to antimicrobial agents. 
Open Microbiol J. 2017;11:53-62.
6. Nogva HK,Dromtorp SM, Nissen H, Rudi K. Ethidium monoa-
zide for DNA- based differentiation of viable and dead bacteria by 
5’-nuclease PCR. Biotechniques. 2003;34:804-8.
7. Nocker A, Cheung CY, Camper AK. Comparison of propidium 
monoazide for differentiation of live vs. dead bacteria by selective re-
moval of DNA from dead cells. J Microbiol Methods. 2006;67:310-20.
8. Rudi K, Moen B, Dromtorp SM, Holck AL. Use of ethidium mono-
azide and PCR in combination for quantifica-tion of viable and dead 
cells in complex samples. Appl Environ Microbiol. 2005;71:1018-24.
9. Cawthorn DM, Witthuhn RC. Selective PCR detection of vi-
able Enterobacter Sakazakii cells utilizing propidium monoazide or 
ethidium bromide monoazide. Microbiology. 2008;105:1178-85.
10. Nocker A, Sossa-Fernández P, Burr MD, Camper AK. Use of 
propidium monoazide for live/dead distinction in microbial ecology. 
Appl Environ Microbiol. 2007;73:5111-7.
11. Esposito M, Grusovin MG, Worthington HV. Interventions for 
replacing missing teeth : treatment of peri-implantitis. Cochrane 
Collab. 2012;18:1-54.
12. Hägi TT, Hofmänner P, Salvi GE, Ramseier CA, Sculean A. 
Clinical outcomes following subgingival application of a novel 
erythritol powder by means of air polishing in supportive periodon-
tal therapy: a randomized, controlled clinical study. Quintessence 
Int. 2013;44:753-61.
13. Drago L, Bortolin M, Taschieri S, De Vecchi E, Agrappi S, Del 
Fabbro M, et al. Erythritol/chlorhexidine combination reduces mi-
crobial biofilm and prevents its formation on titanium surfaces in 
vitro. J Oral Pathol Med. 2017;46:625-31.
14. Moharrami M, Perrotti V, Iaculli F, Love RM, Quaranta A. 
Effects of air abrasive decontamination on titanium surfaces: A 
systematic review of in vitro studies. Clin Implant Dent Rel Res. 
2019;21:398-421.
15. Blanc V, Isabal S, Sánchez MC, Llama-Palacios A, Herrera D, Sanz 
M, et al. Characterization and application of a flow system for in vitro 
multispecies oral biofilm formation. J Periodontal Res. 2014;49:323-32.
16. Àlvarez G, González M, Isabal S, Blanc V, León R. Method to 
quantify live and dead cells in multi-species oral biofilm by real-time 
PCR with propidium monoazide. AMB Express. 2013;3:1-8.
17. Vaughan BL, Smith BG, Chopp DL. The influence of fluid flow 
on modeling quorum sensing in bacterial biofilms. Bull Math Biol. 
2010;72:1143-6.
18. Sahrmann P, Ronay V, Sener B, Jung RE, Attin T, Schmidlin PR. 
Cleaning potential of glycine air-flow application in an in vitro peri-
implantitis model. Clin Oral Implants Res. 2013;24:666-70.
19. Derks J, Tomasi C. Peri-implant health and disease. A systematic 
review of current epidemiology. J Clin Periodontol. 2015;42:S158-71.
20. Cercadillo-Ibarguren I, Sánchez-Torres A, Figueiredo R, 
Schwarz F, Gay-Escoda C, Valmaseda-Castellón E. Immediately 
loaded implant-supported full-arches: Peri-implant status after 1-9 
years in a private practice. J Dent. 2017;67:72-6.
21. Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, 
Camargo PM, et al. Peri-implant diseases and conditions: Consensus 
report of workgroup 4 of the 2017 world workshop on the classifica-
tion of periodontal and peri-implant diseases and conditions. J Peri-
odontol. 2018; 89:S313-8.
22. Fürst MM, Salvi GE, Lang NP, Persson GR. Bacterial coloniza-
tion immediately after installation on oral titanium implants. Clin 
Oral Implants Res. 2007;18:501-8.
23. Cortés-Acha B, Figueiredo R, Seminago R, Roig FJ, Llorens C, 
Valmaseda-Castellón E. Microbiota analysis of biofilms on experi-
mental abutments mimicking dental implants: An in vivo model. J 
Periodontol. 2017;88:1090-104.
24. Cortés-Acha B, Figueiredo R, Blanc V, Soler-Ollé A, León R, 
Valmaseda-Castellón E. Development and viability of biofilms 
grown on experimental abutments mimicking dental implants: An in 
vivo model. Med Oral Patol Oral Cir Bucal. 2019;24:e511-7.
25. Muthukuru M, Zainvi A, Esplugues EO, Flemmig TF. Non-sur-
gical therapy for the management of peri-implantitis: A systematic 
review. Clin Oral Implant Res. 2012;23:77-83.
26. Mensi M, Cochis A, Sordillo A, Uberti F, Rimondini L. Biofilm 
removal and bacterial re-colonization inhibition of a novel erythri-
tol/chlorhexidine air-polishing powder on titanium disks. Materials 
(Basel). 2018;11:1-13.
27. Drago L, Del Fabbro M, Bortolin M, Vassena C, De Vecchi 
E, Taschieri S. Biofilm removal and antimicrobial activity of two 
different air-polishing powders: An in vitro study. J Periodontol. 
2014;85:e363-9.
28. Schmidt KE, Auschill TM, Heumann C, Frankenberger R, Eick 
S, Sculean A, et al. Influence of different instrumentation modalities 
on the surface characteristics and biofilm formation on dental im-
plant neck, in vitro. Clin Oral Implants Res. 2017;28:483-90.
29. Cochis A, Fini M, Carrassi A, Migliario M, Visai L, Rimondini 
L. Effect of air polishing with glycine powder on titanium abutment 
surfaces. Clin Oral Implants Res. 2013;24:904-9.
30. Matsubara VH, Leong BW, Leong MJL, Lawrence Z, Becker T, 
Quaranta A. Cleaning potential of different air abrasive powders and 
their impact on implant surface roughness. Clin Implant Dent Relat 
Res. 2020;22:96-104.
31. Hashino E, Kuboniwa M, Alghamdi SA, Yamaguchi M, Yama-
moto R, Cho H, et al. Erythritol alters microstructure and metabo-
lomic profiles of biofilm composed of Streptococcus gordonii and 
Porphyromonas gingivalis. Mol Oral Microbiol. 2013;28:435-51.
32. Janus MM, Volgenant CMC, Brandt BW, Buijs MJ, Crielaard W, 
Zaura E, et al. Effect of erythritol on microbial ecology of in vitro 
gingivitis biofilms. J Oral Microbiol. 2017;9:1337477.
Acknowledgements
The authors wish to thank Mary Georgina Hardinge (Native Eng-
lish freelance translator) for English language editing of the manu-
script, Dentaid SL (Cerdanyola del Vallès, Spain) for the help with 
the microbiology analysis, EMS (Nyon, Switzerland) for providing 
the air-flow device, and Avinent (Santpedor, Spain) for donating the 
implants for the study.
Funding
The authors declare non-financial support from EMS (Nyon, Swit-
zerland), Dentaid SL (Cerdanyola del Vallés, Spain) and Avinent 
(Santpedor, Spain) for this study. The present research was conducted 
by the Dental and Maxillofacial Pathology and Therapeutics research 
group at the IDIBELL Institute (L’Hospitalet de Llobregat, Spain).
e610
Med Oral Patol Oral Cir Bucal. 2021 Sep 1;26 (5):e602-10. Erythritol powder and oral biofilm
Conflict of interest
The authors would like to declare the following interests outside the 
work presented:
Patricia Amate-Fernández reports no additional conflicts of interest.
Rui Figueiredo reports grants, personal fees (sponsored lectures) and 
non-financial support from MozoGrau (Valladolid, Spain) and Avi-
nent SA (Santpedor, Spain), grants and non-financial support from 
Dentaid SA (Cerdanyola del Vallès, Spain), personal fees (sponsored 
lectures) from BioHorizons Ibérica (Madrid, Spain), Inibsa Dental 
(Lliça de Vall, Spain), Dentsply implants Iberia (Barcelona, Spain) 
and Araguaney Dental (Barcelona, Spain) outside the sub-mitted 
work. Rui Figueiredo has also participated as a principal investiga-
tor in a randomized clinical trial sponsored by Mundipharma (Cam-
bridge, UK) and in another clinical trial as a sub-investigator for 
Menarini Richerche (Florence, Italy).
Eduard Valmaseda-Castellón reports personal fees (sponsored lec-
tures) and non-financial support from MozoGrau (Valladolid, Spain) 
and Avinent SA (Santpedor, Spain), grants and non-financial support 
from Dentaid SL (Cerdanyola del Vallès, Spain), and personal fees 
(sponsored lectures) from BioHorizons Ibérica (Madrid, Spain), Inibsa 
Dental (Lliça de Vall, Spain) and Dentsply implants Iberia (Barcelona, 
Spain) outside the submitted work. In addition, Eduard Valmaseda-
Castellón has also participated as a sub-investigator in a random-
ized clinical trial spon-sored by Mundipharma (Cambridge, UK).
Vanessa Blanc, Gerard Àlvarez and Rubén León are researchers from 
the Dentaid Research Center (Dentaid, Cerdanyolla del Vallès, Spain).
Ethics
Not applicable since this study has an in vitro design. Thus, an ethics 
approval is not necessary.
Authors contributions
Patricia Amate-Fernández: Design of the study; acquisition and in-
terpretation of the data, drafting of the article, approval of the final 
version of the manuscript and agreement to be accountable for all 
aspects of the work. Rui Figueiredo: Conception and design of the 
study, analysis and interpretation of the data, drafting of the manu-
script, approval of the final version of the manuscript and agreement 
to be accountable for all aspects of the work.; Vanessa Blanc: Design 
of the study; analysis and interpretation of the data, critical revision 
of the manuscript, approval of the final version of the manuscript and 
agreement to be accountable for all aspects of the work. Gerard Àl-
varez: Acquisition of the data, drafting of the article, approval of the 
final version of the manuscript and agreement to be accountable for 
all aspects of the work.; Rubén León: Design of the study, interpreta-
tion of the data, critical revision of the manuscript, approval of the fi-
nal version of the manuscript and agreement to be accountable for all 
aspects of the work.; Eduard Valmaseda-Castellón: Conception and 
design of the study; analysis and interpretation of the data, critical 
revision of the manuscript, approval of the final version of the manu-
script and agreement to be accountable for all aspects of the work.
